ArticleInternational journal of urology : official journal of the Japanese Urological Association2026
Prescribing Patterns and Treatment Persistence for Overactive Bladder in Japan Across Medical Specialties and Facility Types: A Nationwide Claims Database Study.
Article in International journal of urology : official journal of the Japanese Urological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectivesTo describe real-world initial pharmacotherapy, treatment persistence, and diagnostic testing for overactive bladder in Japan by medical specialty and facility type.
methodsThis retrospective descriptive study used nationwide administrative claims data. Patients aged 15 years or older diagnosed with overactive bladder in 2022 who newly initiated pharmacotherapy were followed for 1 year. Analyses were conducted across four groups defined by medical specialty and facility type. We summarized initial medication, baseline comorbidities, one-year treatment persistence, and performance of urinalysis and postvoid residual volume measurement at diagnosis and within 1-3 months thereafter.
resultsOf 702 078 patients diagnosed with overactive bladder, 65 173 met the eligibility criteria (median age 80 years; interquartile range 74.0-85.0; women 56.3%). β3-adrenoceptor agonists accounted for more than 70% of initial prescriptions in both urology and internal medicine, whereas anticholinergics were used more often in internal medicine than in urology. Baseline comorbidities, including dementia, were broadly similar between patients initiating β3-adrenoceptor agonists and those initiating anticholinergics, except for benign prostatic hyperplasia. At 1 year, persistence was higher for β3-adrenoceptor agonists than for anticholinergics and other drugs, but remained below 30% for β3-adrenoceptor agonists. Urinalysis and postvoid residual volume measurement were performed more frequently in urology than in internal medicine.
conclusionsβ3-adrenoceptor agonists predominated as initial pharmacotherapy for overactive bladder in Japan, whereas anticholinergics were used more often in internal medicine than in urology. Similar comorbidity profiles and specialty-related differences in diagnostic testing highlight opportunities to optimize individualized prescribing and strengthen guideline-concordant evaluation across care settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.